Heat therapy with gold nanoparticles for skin melanoma
Part of Injuries & trauma clinical trials.
This trial tests a new therapy that uses tiny gold particles to heat and destroy melanoma tumors on the skin or just under the skin. It is for people whose melanoma has spread and has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 or older.
- You have advanced melanoma (stage 3C, 3D, or 4) that has spread, with at least one skin tumor that can be seen and reached.
- Your tumors must be 2.5 cm or smaller in size.
- You have already tried at least one standard treatment (like immunotherapy) and it didn't work.
- You are generally able to care for yourself (ECOG score of 0 or 1) and expected to live at least 6 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where a tiny gold particle is injected into skin tumors and then heated to destroy cancer cells. It is for people with advanced melanoma that has not responded to standard therapies like immunotherapy.
This study tests a new treatment combining gold nanoparticles (Au-TMP), radiation therapy, and an immune-boosting drug (anti-PD-1) for advanced melanoma that cannot be surgically removed. The goal is to help your immune system fight the cancer more effectively.
This trial tests whether adding heat therapy (hyperthermia) to radiation therapy works well for older adults with larger non-melanoma skin cancers. It may help shrink tumors without needing surgery.
This study tests if adding heat therapy (hyperthermia) to immunotherapy can help people with advanced stomach or colorectal cancer that has spread to the liver. It's for patients who have already tried other treatments and are looking for new options.
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.
Hear when a new Cutaneous Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.